Cassava Paying $40 Million to Settle Doctored Alzheimer's Drug Data Claims




The Securities and Exchange Commission alleged that a researcher for the company manipulated trial data to make its drug results look more promising.

Leave a Reply

Your email address will not be published. Required fields are marked *